Denosumab, an anti-RANKL antibody, offers promise for patients with renal dysfunction who cannot tolerate bisphosphonates, while odanacatib shows comparable efficacy to bisphosphonates with minimal impact on bone formation. Here, TNFSF11 is linked to Abnormal renal physiology.